ASCO GU 2026

ASCO GU 2026: Belzutifan plus pembrolizumab post-surgery helps ccRCC patients at high risk for relapse stay cancer-free longer

ASCO GU 2026: Blood test predicts which bladder cancer patients may safely skip surgery

ASCO GU 2026: Combo targeting blood vessel growth controls ccRCC better than single agent

ASCO GU 2026: Enfortumab vedotin pembrolizumab combo may reduce risk of recurrence for some MIBC cases

ASCO GU 2026: Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery

ASCO GU 2026: Cancer’s clues in the bloodstream reveal the role androgen receptor alterations play in metastatic prostate cancer

mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Microplastics found at higher levels in prostate cancer tissue compared to benign tissue

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA

Real-world cardiovascular risks with novel hormonal therapies in advanced prostate cancer

Circulating tumour DNA shows high accuracy for monitoring testicular cancer across all stages

First real-world study of penile cancer in Bolivia reveals high HPV-related rates and advanced disease

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer

Belzutifan plus palbociclib shows modest activity with manageable safety in heavily pretreated kidney cancer

Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer

HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer

Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery

Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer

225Ac-PSMA-trillium shows high PSA response and favourable safety in metastatic castration-resistant prostate cancer

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC

Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL in mHSPC

Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension

Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control

QoL outcomes are inconsistently reported in contemporary phase III genitourinary cancer trials

Cytoreductive SBRT with ipilimumab and nivolumab in de novo mRCC shows no PFS benefit but is safe

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC

ArteraAI MMAI enhances prediction of biochemical recurrence and metastasis in localised prostate cancer

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows promising responses in metastatic clear cell RCC

ASCO GU 2026: Updates in renal cancer

ASCO GU 2026: Updates in bladder cancer

ASCO GU 2026: Updates in metastatic prostate cancer

ASCO GU 2026: Updates in localised prostate cancer

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance

Real-world outcomes after post-Lu177 therapy in mCRPC show limited survival and heterogeneous treatment patterns

Evaluation and definition of response and progression from trials to clinical practice

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer